Related Experiment Videos
New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy
1Department of Oncology and Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract:
Some men affected with clinically localized prostate carcinoma suffer life-threatening recurrence, despite previous treatment with surgery or radiation therapy, underscoring the need for new, effective, systemic adjuvant treatment approaches. Recent molecular mechanism-based prostate cancer drug discovery efforts have identified several candidate targets for systemic prostate cancer adjuvant therapy; however, traditional cancer treatment development algorithms may not be appropriate for many of the new treatment strategies. To best exploit the clinical potential of these molecular treatment strategies, novel translational research strategies are required to support hypothesis-driven clinical research and development.
Insights
Effective systemic adjuvant treatments are needed for prostate carcinoma recurrence after surgery or radiation. Novel translational research strategies are required to advance molecularly targeted therapies for prostate cancer.
Area of Science:
- Oncology
- Translational Research
Background:
- Prostate carcinoma recurrence can be life-threatening despite initial treatments like surgery or radiation.
- There is a critical need for novel systemic adjuvant therapies to manage recurrent prostate cancer.
Purpose of the Study:
- To highlight the inadequacy of traditional drug development algorithms for novel molecularly targeted prostate cancer therapies.
- To advocate for new translational research strategies to support the clinical development of these targeted treatments.
Main Methods:
- Review of current challenges in prostate cancer treatment development.
- Analysis of molecular mechanism-based drug discovery efforts.
- Proposal for novel translational research approaches.
Main Results:
- Traditional cancer treatment development pathways are insufficient for emerging molecularly targeted prostate cancer therapies.
- Existing approaches may not adequately exploit the potential of new drug targets.
Conclusions:
- Novel translational research strategies are essential for advancing systemic adjuvant treatments for prostate cancer.
- These strategies will facilitate hypothesis-driven clinical research and development for molecularly targeted therapies.